Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:52 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 1,596 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Allogeneic Transplant Clear all

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions: Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Questionnaire Administration, Tagraxofusp-erzs; Drug · Procedure · Other + 1 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Cytomegalovirus Infections
Interventions: CMV CTL infusion; Biological
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Not listed
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Acute Lymphocytic Leukemia
Interventions: Inotuzumab Ozogamicin; Drug
Lead sponsor: Leland Metheny; Other
Eligibility: 16 Years to 75 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 7
States / cities: Westwood, Kansas • Boston, Massachusetts • Omaha, Nebraska + 3 more

Conditions: Lymphoma, Myeloma, Leukemia, Myelodysplasia, Solid Tumors
Interventions: Campath Purged Non-myeloablative ASCT, Donor Apheresis; Drug · Procedure
Lead sponsor: David Rizzieri, MD; Other
Eligibility: 17 Years and older
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2013
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Preleukemia, Myeloproliferative Disorders, Lymphoma, Myeloma, Graft Versus Host Disease
Interventions: Fludarabine, Melphalan, Campath; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Leukemia, Myeloproliferative Disorders, Myelodysplastic-Myeloproliferative Diseases
Interventions: Allogeneic bone marrow transplantation, Peripheral blood stem cell transplantation; Biological
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: Up to 66 Years
Enrollment: 551 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2014
U.S. locations: 39
States / cities: Birmingham, Alabama • Duarte, California • La Jolla, California + 32 more

Conditions: Aplastic Anemia
Interventions: cyclophosphamide, anti-thymocyte globulin, cyclosporine, allogeneic bone marrow transplantation, methotrexate, DNA analysis, flow cytometry, polymorphism analysis, laboratory biomarker analysis; Drug · Biological · Procedure + 2 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Up to 65 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 3
States / cities: Salt Lake City, Utah • Seattle, Washington • Milwaukee, Wisconsin

Conditions: DiGeorge Syndrome, Complete Typical DiGeorge Anomaly
Interventions: Cultured Thymus Tissue for Implantation (CTTI); Biological
Lead sponsor: Sumitomo Pharma Switzerland GmbH; Industry
Eligibility: Not listed
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1991 – 2017
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Non-Hodgkin's Lymphoma, Leukemia, Multiple Myeloma, Acute Myeloid Leukemia, Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndrome
Interventions: Thymoglobulin, Total-Body Irradiation, Allogeneic PBSCT or BMT, Tacrolimus, Mycophenolate Mofetil; Biological · Radiation · Procedure + 1 more
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 40 Years to 70 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2017
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome
Interventions: Biospecimen Collection, Olutasidenib; Procedure · Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Duarte, California • Cleveland, Ohio

Conditions: Sickle Cell Disease, Thalassemia
Interventions: CordIn; Biological
Lead sponsor: Gamida Cell ltd; Industry
Eligibility: 2 Years to 25 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Oakland, California • Washington D.C., District of Columbia

Conditions: GVHD
Interventions: CelluTome® Epidermal Harvesting System; Device
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions: lenalidomide; Drug
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Peripheral T-cell Lymphomas, Lymphoproliferative Disorders, Immune System Diseases
Interventions: ATL-RIC, mRIC, allo HCT, RIC, GVHD prophylaxis, IOC; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Years to 120 Years
Enrollment: 118 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2030
U.S. locations: 2
States / cities: Bethesda, Maryland • Minneapolis, Minnesota

Conditions: Graft vs Host Disease, Hematologic Neoplasm, Leukemia, Multiple Myeloma, Myelodysplastic Syndrome
Interventions: Allogeneic Bone Marrow Transplant; Procedure
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 10 Years to 55 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cytomegalovirus (CMV)-Positive Recipients, Allogeneic, Hematopoietic Cell Transplant (HCT)
Interventions: ASP0113, Placebo; Biological · Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 514 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 27
States / cities: Birmingham, Alabama • Tucson, Arizona • San Francisco, California + 22 more

Conditions: Tooth Loss
Interventions: Particulate bone graft, Autogenous dental pulp tissue, Resorbable collagen membrane, Suture; Other
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Adenovirus
Interventions: Brincidofovir, Standard of Care; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years to 99 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 4
States / cities: Los Angeles, California • Chicago, Illinois • Boston, Massachusetts + 1 more

Conditions: Fanconi Anemia
Interventions: cyclophosphamide, cyclosporine, methotrexate, allogeneic bone marrow transplantation, nonmyeloablative allogeneic hematopoietic stem cell transplantation; Drug · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Not listed
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 2
States / cities: Seattle, Washington

Conditions: Mycosis Fungoides, Sezary Syndrome
Interventions: A matched peripheral donor stem cells, cyclosporine, fludarabine, Campath; Other · Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Fluid Overload
Interventions: Bioimpedance device; Diagnostic Test
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 6 Years to 21 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Leukemia
Interventions: Interferon alpha-2B (IFN-α) 3 million units (MU) subcutaneous daily; Drug
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Leukemia, Myelodysplastic Syndromes
Interventions: anti-thymocyte globulin, peripheral blood lymphocyte therapy, fludarabine phosphate, methylprednisolone, thiotepa, allogeneic hematopoietic stem cell transplantation, in vitro-treated peripheral blood stem cell transplantation, total-body irradiation; Biological · Drug · Procedure + 1 more
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: Up to 50 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2018
U.S. locations: 6
States / cities: Los Angeles, California • Gainesville, Florida • Boston, Massachusetts + 1 more

Conditions: Acute Myeloid Leukemia
Interventions: gilteritinib, Placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 356 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 46
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 35 more

Search by objective public record fields.

Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant

Cytotoxic T-Lymphocytes for the Prophylaxis of Cytomegalovirus After Allogeneic Stem Cell Transplant

Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia

Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath

Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies

Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201)

Cyclophosphamide and Anti-thymocyte Globulin Followed By Methotrexate and Cyclosporine in Preventing Chronic Graft-Versus-Host Disease in Patients With Severe Aplastic Anemia Undergoing Donor Bone Marrow Transplant

Thymus Transplantation in DiGeorge Syndrome #668

Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT

Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant

Allogeneic SCT of CordIn™, in Patients With Hemoglobinopathies

Allogeneic Skin Grafting

Lenalidomide in Treating Patients With Progressive or Recurrent Multiple Myeloma After a Donor Stem Cell Transplant

Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma

Bone Marrow Transplant Studies for Safe and Effective Treatment of Leukemia

A Study to Evaluate a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)

The Use of Dental Pulp Tissue as an Autogenous Graft for Ridge Augmentation

Open Label Study of IV Brincidofovir in Adult Transplant Recipients With Adenovirus Viremia

Cyclophosphamide in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Fanconi's Anemia

Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome

Using Bioimpedance Analysis to Monitor Fluid Status in Children

IFN-DLI for Relapsed Acute Leukemia After Allo-SCT

Laboratory-Treated Lymphocyte Infusion After Haploidentical Donor Stem Cell Transplant

A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)